About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
K
Double-Hit Lymphoma Diagnosis, Initial and Relapsed/Refractory Treatment Options, Novel Agents, and Approaches
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Kieron Dunleavy
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Kieron Dunleavy
118 views
October 17, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…
05:38
GRACE
Epcoritamab in NHL - Incidence and Management of CRS
Feat.
T. Phillips
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
26:58
Total Health
Update on Cellular Therapy in Lymphoma
Feat.
B. Randolph
33:11
Total Health
Bispecific Antibodies and CAR T-Cells for NHL: Challenges and Opport…
Feat.
K. Komanduri
10:49
Monia Marchetti
Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…
42:09
University of Colorado Department of Medicine
Immunotherapy in Lymphomas: The Present and the Future
Feat.
M. Kamdar
06:38
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Updated Results From EPCORE NHL-1 - Effec…
Feat.
Y. Karimi
08:02
ASH 2022 Conference Coverage
ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…
Feat.
S. Holtan
18:18
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Emerging BCL2 Inhibitors
Feat.
M. Ann Anderson
05:04
ASH 2022 Conference Coverage
ASH 2022 Phase III SUNMO Trial: Evaluating the Efficacy & Safety…
Feat.
J. Westin
17:36
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: The Emergence of Bispecific Antibodies in Aggressive B-Ce…
Feat.
M. Hutchings
11:12
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: Indolent B-Cell Lymphoma
Feat.
L. Nastoupil
14:36
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
The Latest Data on New Therapies in FL and MZL
Feat.
J. Carter
12:43
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Bispecific Antibodies or CAR T-Cells for Indolent B-NHL?
Feat.
C. Jacobson
13:22
SOHO 2022 Tenth Annual Meeting
SOHO 2022: The Next Generation of Novel Agents in Development for Ag…
Feat.
J. Westin
38:55
Indy Hematology Review
Managing Indolent and Mantle Cell Lymphomas With Targeted and Cellul…
Feat.
G. Salles
